A Phase I Study of ARQ 197 in Combination With IV Topotecan in Advanced Solid Tumors With an Expansion Cohort in Small Cell Lung Cancer
Phase of Trial: Phase I
Latest Information Update: 05 Apr 2018
At a glance
- Drugs Tivantinib (Primary) ; Topotecan (Primary)
- Indications Small cell lung cancer; Solid tumours
- Focus Adverse reactions
- 02 Apr 2018 Status changed from active, no longer recruiting to completed.
- 17 Apr 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2017.
- 10 Jun 2016 Planned primary completion date changed from 1 Mar 2016 to 1 Dec 2016.